Turning Back Time: The Science of Aging

Panel Overview and Core Philosophy

• The field of geroscience aims to shift medicine from treating individual chronic diseases to targeting the underlying biology of aging itself.
• Panelists argue that aging is a modifiable risk factor for all chronic diseases, rather than an inevitable consequence of time.
• The primary goal is "healthspan compression," defined as extending the period of healthy life so that death occurs suddenly near the end of life (e.g., from an accident) rather than after decades of morbidity.
• Centenarian data indicates a "longevity dividend," where those living to 100 compress morbidity and incur only 30% of the medical costs of those dying at 70–80.
• The panelists reject the label of "aging as a disease" for regulatory and social reasons (avoiding ageism), preferring the term "prevention of a cluster of age-related diseases."

Specific Research and Drug Development Initiatives

• Nir Barzilai (Albert Einstein College of Medicine):
  • Research focuses on "compression of morbidity" observed in centenarians, noting that 70% develop disease rapidly near the end, while 30% die suddenly without prolonged illness.
  • Leading the TAME (Targeting Aging with Metformin) trial, which aims to enroll 3,000 participants aged 65–80 to prove that delaying aging prevents multiple diseases.
  • TAME uses a composite endpoint (any of diabetes, heart disease, Alzheimer's, cancer, or death) to increase statistical power and reduce trial size compared to single-disease trials.
  • TAME will utilize methylation, proteomic, and metabolic biomarkers to accelerate trial timelines, avoiding the need for 50-year longevity studies.
• Christopher Healy (RestorBio):
  • Developing a TORC1 inhibitor that mimics intermittent fasting by inhibiting the protein complex only during specific parts of the day, unlike current drugs that inhibit it continuously.
  • Current Phase 3 trials target respiratory tract infections, the fourth leading cause of hospitalization for those over 65, to prove immune function improvement in aging.
  • Drug efficacy is highest in the 85+ demographic, demonstrating that biological "tuning" works even in advanced age.
  • The approach targets the immune system as a single aging organ system before expanding to broader applications.
• Howard Federoff (Alzheimer's Drug Discovery Foundation):
  • Highlights that 40% of people at age 80 and 50% at age 85+ have Alzheimer's pathology, with aging being the primary risk factor.
  • Notes that 75% of current Alzheimer's drugs in development are non-amyloid agents targeting aging-related inflammation.
  • Funding a trial to test if metformin improves brain glucose utilization (via FDG-PET scanning) in Alzheimer's patients, serving as a proof-of-concept for repurposing existing drugs.
  • Advocates for "cocktail therapies" (similar to cancer or HIV treatment) involving combinations of anti-inflammatories, senolytics, and amyloid-targeting drugs.
• Joan Manik (Restore Bio):
  • Emphasizes that small molecules (like TORC1 inhibitors) offer a safer, faster path to approval compared to gene therapy, requiring "tuning" of pathways rather than replacement.
  • Discusses the potential for repurposed drugs to generate new commercial value through reformulation, new chemistry, or data exclusivity.

Economic, Regulatory, and Ethical Considerations

• Regulatory Strategy: Without an official "aging" indication, drugs must be developed for specific diseases (e.g., respiratory infections, diabetes prevention) to gain FDA approval and insurance coverage.
• Cost Efficiency: Treating aging via a single broad intervention is projected to be cheaper than treating individual diseases separately; for example, the TAME trial is smaller (3,000 participants) because it counts multiple outcomes.
• Metformin Economics: Metformin is extremely cheap ($40 for 600 tablets), making it a potential first-line aging intervention, though future targeted drugs may be expensive until they go generic.
• Trial Design Challenges: Regulators and sponsors are hesitant to fund "aging" trials due to the long duration required; using composite endpoints and biomarkers is the proposed solution.
• Safety and Ethics: Concerns exist regarding long-term use (decades) and the ethical implications of treating healthy middle-aged populations; trials are currently focused on the 65–80 age group where disease risk is high.

Societal Impact and Lifestyle Interventions

• Lifestyle Factors: Panelists identify exercise as the number one intervention for aging, followed by intermittent fasting and plant-based diets rich in polyphenols (antioxidants) to combat inflammation.
• Metformin vs. Exercise: A new study indicates that while metformin may slightly reduce muscle size compared to exercise alone, it prevents exercise-induced inflammation and oxidative damage, resulting in equal or better muscle force.
• Societal Shifts: Increased healthspan will require adjustments to retirement ages, pension systems, and workforce participation to utilize the wisdom and productivity of older adults.
• Global Equity: Experts debate whether new drugs will be accessible globally, noting that public health measures (vaccines, sanitation) remain the most efficient method for increasing life expectancy in developing nations.
• Future Outlook: The panel projects a gradual extension of healthspan (2–3 years at a time) rather than an immediate leap to 100+ years, with society needing to adapt to longer working lives and intergenerational integration.